PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性研究

发布时间：2018-06-28 18:52

本文选题：外周动脉疾病 + 氯吡格雷　；参考：《中国药房》2017年26期

【摘要】：目的:探讨外周动脉疾病(PAD)患者基因多态性与氯吡格雷抗血小板疗效的相关性。方法:收集近年来国内外相关文献,就PAD患者基因多态性与氯吡格雷抗血小板疗效的相关性进行汇总、分析。结果与结论:目前已发现多种与氯吡格雷抗血小板疗效和主要心血管不良事件(MACE)相关的基因,包括细胞色素P_(450)(CYP)2C19、腺苷三磷酸结合盒B亚家族成员1(ABCB1)、对氧磷酶1(PON1)和腺苷二磷酸P2Y12受体(P2Y12)等。其中,CYP2C19~*2、~*3等位基因可能会减弱氯吡格雷的抗血小板作用,两者的相关性已被多项研究证实,且结果具有广泛的一致性;ABCB1 C3435T、PON1 Q192R位点发生突变,可能会导致患者对氯吡格雷的反应性变低,增加MACE发生的风险,但缺乏大规模的前瞻性临床研究,且现有结果并不一致;尚未发现PAD患者P2Y12基因多态性与氯吡格雷疗效显著相关。
[Abstract]:Objective: To investigate the correlation between gene polymorphism of peripheral arterial disease (PAD) and the effect of clopidogrel on antiplatelet effect. Methods: a collection of relevant literature at home and abroad in recent years was collected, and the correlation between gene polymorphism of PAD patients and clopidogrel antiplatelet effect was collected and analyzed. Conclusion: a variety of clopidogrel and clopidogrel have been found to be anti blood. The genes associated with the plate effect and major cardiovascular adverse events (MACE), including cytochrome P_ (450) (CYP) 2C19, 1 (ABCB1) of the adenosine three phosphate binding cassette B subfamily, PON1 and adenosine two phosphate P2Y12 receptor (P2Y12), which may weaken the antiplatelet effect of clopidogrel, both of which may be reduced. The correlation has been confirmed by a number of studies, and the results have extensive consistency. The mutation of ABCB1 C3435T and PON1 Q192R loci may cause the patients to lower the responsiveness to clopidogrel and increase the risk of MACE, but there is no large prospective clinical study, and the results are not consistent. There has not been much P2Y12 gene in PAD patients. The state of state is significantly related to the efficacy of clopidogrel.
【作者单位】：首都医科大学附属北京安贞医院药剂科;
【基金】：“重大新药创制”科技重大专项(No.2012ZX09303016)
【分类号】：R543

【相似文献】